- Relationship to Diabetes
- At risk of diabetes
Supply of NovoRapid® Penfill® (insulin aspart) for people living with diabetes in the UK
Novo Nordisk UK is aware that there is currently a stock shortage of its medicine NovoRapid® (insulin aspart) Penfill® for people living with diabetes in the UK. The shortage is temporary and is due to an unforeseen delay in delivery of the next order of this medicine.
We would like to reassure people living with diabetes in the UK that alternative treatment options are available and options can be discussed with their healthcare professional. The shortage is not a consequence of any safety or quality related concern with NovoRapid®.
We are in discussions with the Medicines and Healthcare products Regulatory Agency (MHRA), patient organisations, pharmacies, and healthcare professionals to monitor our stock levels and to return to a stable level of supply that remains consistent with the needs of patients and the NHS as swiftly as possible.
Ensuring a continuous supply that meets the needs of patients and the NHS is of utmost importance for Novo Nordisk. Novo Nordisk is working to remedy the shortage and remains committed to ensuring people with diabetes receive the treatment they need.
Novo Nordisk UK is aware that there is currently a stock shortage of its medicine NovoRapid® (insulin aspart) Penfill® for people living with diabetes in the UK. The shortage is temporary and is due to an unforeseen delay in delivery of the next order of this medicine.
We would like to reassure people living with diabetes in the UK that alternative treatment options are available and options can be discussed with their healthcare professional. The shortage is not a consequence of any safety or quality related concern with NovoRapid®.
We are in discussions with the Medicines and Healthcare products Regulatory Agency (MHRA), patient organisations, pharmacies, and healthcare professionals to monitor our stock levels and to return to a stable level of supply that remains consistent with the needs of patients and the NHS as swiftly as possible.
Ensuring a continuous supply that meets the needs of patients and the NHS is of utmost importance for Novo Nordisk. Novo Nordisk is working to remedy the shortage and remains committed to ensuring people with diabetes receive the treatment they need.